Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key diabetes drug Victoza until 2023.

Victoza (liraglutide) is a prescription drug used to treat type 2 diabetes and reduce certain heart risks. Its mechanism of action is mimicking a natural hormone (GLP-1) that manages your blood ...

Novo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as a treatment for type 2 diabetes in children for almost two decades. The FDA says the okay ...

Victoza (liraglutide) and Ozempic (semaglutide) are two injectable drugs known as GLP-1 agonists used to treat people with ...